Dogwood Therapeutics Inc. (NASDAQ: DWTX) announced positive interim results from its Phase 2b clinical trial testing Halneuron for chemotherapy-induced neuropathic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE